- Home
- MSI vs CANF Comparison
MSI vs CANF Comparison
Compare MSI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSI
- CANF
- Stock Information
- Founded
- MSI 1928
- CANF 1994
- Country
- MSI United States
- CANF Israel
- Employees
- MSI N/A
- CANF N/A
- Industry
- MSI Radio And Television Broadcasting And Communications Equipment
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- MSI Technology
- CANF Health Care
- Exchange
- MSI Nasdaq
- CANF Nasdaq
- Market Cap
- MSI 67.6B
- CANF 14.8M
- IPO Year
- MSI N/A
- CANF N/A
- Fundamental
- Price
- MSI $419.17
- CANF $1.07
- Analyst Decision
- MSI Strong Buy
- CANF Strong Buy
- Analyst Count
- MSI 9
- CANF 2
- Target Price
- MSI $505.11
- CANF $14.00
- AVG Volume (30 Days)
- MSI 859.3K
- CANF 137.8K
- Earning Date
- MSI 07-31-2025
- CANF 04-14-2025
- Dividend Yield
- MSI 1.04%
- CANF N/A
- EPS Growth
- MSI 45.79
- CANF N/A
- EPS
- MSI 11.91
- CANF N/A
- Revenue
- MSI $10,956,000,000.00
- CANF $674,000.00
- Revenue This Year
- MSI $6.61
- CANF $461.72
- Revenue Next Year
- MSI $5.69
- CANF N/A
- P/E Ratio
- MSI $35.27
- CANF N/A
- Revenue Growth
- MSI 7.45
- CANF N/A
- 52 Week Low
- MSI $384.51
- CANF $0.98
- 52 Week High
- MSI $507.82
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- MSI 53.93
- CANF 39.89
- Support Level
- MSI $411.60
- CANF $1.02
- Resistance Level
- MSI $421.33
- CANF $1.09
- Average True Range (ATR)
- MSI 5.93
- CANF 0.04
- MACD
- MSI 1.16
- CANF -0.00
- Stochastic Oscillator
- MSI 82.48
- CANF 6.67
About MSI Motorola Solutions Inc.
Motorola Solutions is a leading provider of communications and analytics, primarily serving public safety departments as well as schools, hospitals, and businesses. The bulk of the firm's revenue comes from sales of land mobile radios and radio network infrastructure, but the firm also sells surveillance equipment and dispatch software. Most of Motorola's revenue comes from government agencies, while roughly 25% comes from schools and private businesses. Motorola has customers in over 100 countries and in every state in the United States.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).